| Literature DB >> 34181928 |
Ari Dienel1, Remya A Veettil1, Kanako Matsumura1, H Alex Choi2, Peeyush Kumar T1, Andrey S Tsvetkov3, Jaroslaw Aronowski4, Pramod Dash5, Spiros L Blackburn1, Devin W McBride6.
Abstract
Subarachnoid hemorrhage (SAH) results in severe neuronal dysfunction and degeneration. Since the nicotinic acetylcholine α7 receptors (α7-AChR) are involved in neuronal function and survival, we investigated if stimulation of α7-AChR would promote neuronal survival and improve behavioral outcome following SAH in mice. Male mice subjected to SAH were treated with either galantamine (α7-AChR agonist) or vehicle. Neurobehavioral testing was performed 24 h after SAH, and mice were euthanized for analysis of neuronal cell death or a cell survival (PI3K/Akt) signaling pathway. Neuron cell cultures were subjected to hemoglobin toxicity to assess the direct effects of α7-AChR agonism independent of other cells. Treatment with the α7-AChR agonist promoted neuronal survival and improved functional outcomes 24 h post-SAH. The improved outcomes corresponded with increased PI3K/Akt activity. Antagonism of α7-AChR or PI3K effectively reversed galantamine's beneficial effects. Tissue from α7-AChR knockout mice confirmed α7-AChR's role in neuronal survival after SAH. Data from the neuronal cell culture experiment supported a direct effect of α7-AChR agonism in promoting cell survival. Our findings indicate that α7-AChR is a therapeutic target following SAH which can promote neuronal survival, thereby improving neurobehavioral outcome. Thus, the clinically relevant α7-AChR agonist, galantamine, might be a potential candidate for human use to improve outcome after SAH.Entities:
Keywords: Galantamine; Neuron survival; Nicotinic acetylcholine receptor; Subarachnoid hemorrhage
Mesh:
Substances:
Year: 2021 PMID: 34181928 PMCID: PMC8359014 DOI: 10.1016/j.expneurol.2021.113792
Source DB: PubMed Journal: Exp Neurol ISSN: 0014-4886 Impact factor: 5.620